Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 18/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | PRKCI | P41743 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31749048 | 0.75 | — | — | |
| SCHEMBL496459 | 0.75 | — | — | |
| SCHEMBL11056586 | 0.67 | PDE3B (0.42) | HSD17B10 | |
| SCHEMBL22045587 | 0.63 | KDM4E (0.34) | ALDH1A1HSD17B10TDP1 | |
| SCHEMBL31686062 | 0.63 | TYMS (0.32) | TYMS | |
| SCHEMBL17950745 | 0.63 | PDPK1 (0.37) | TYMSPARP1 | |
| SCHEMBL873756 | 0.63 | PARP1 (0.54) | TYMSPARP1TDP1 | |
| SCHEMBL874607 | 0.63 | PARP1 (0.54) | TYMSPARP1 | |
| SCHEMBL28960473 | 0.63 | AXL (0.44) | TYMSALDH1A1PARP1HSD17B10TDP1 | |
| SCHEMBL6610267 | 0.63 | PARP1 (0.38) | ALDH1A1PARP1HSD17B10TDP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0599152-A1 | Triazinones and Triazinophthalazinones possessing antiasthmatic/antiallergic, positive inotropic and antihypertensive activities | ASTA Medica Aktiengesellschaft (DE) | 1994-06-01 | — | — | EP | disclosed |